Millennium Pharmaceuticals, Inc. (MLNM) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Icebrg who wrote (1487)	4/22/2003 6:31:17 PM
From: SemiBull	Read Replies (1) of 3044

Millennium Pharma: Got $160M Total Under Aventis Pact Tuesday April 22, 6:02 pm ET WASHINGTON (Dow Jones)--Millennium Pharmaceuticals Inc. said Tuesday that it received notification that Aventis Pharmaceuticals Inc. intends to end the companies' technology transfer agreement. Aventis made a final $40 million payment for the use of technology that has already been transferred from Millennium, according to a document that Millennium filed with the Securities and Exchange Commission (News - Websites). Millennium said the end of the agreement doesn't affect the five-year collaboration and license contract that the companies established in 2000 to develop and commercialize drugs for treating inflammatory diseases. Since entering into the technology transfer pact in 2000, Aventis has paid Millennium $160 million, including the final payment Tuesday, the filing said. The termination of the pact takes effect July 21, the third anniversary of the agreement, which had a term of three to five years, the filing said. -By Robert L. Grant; Dow Jones Newswires; 202-393-7851; robert.grant@dowjones.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next